News

Polyplus-transfection® launches FectoVIR®-AAV

July 23, 2021

Polyplus-transfection® SA, the leading biotechnology company that supports the gene and cell therapy market by supplying innovative transfection solutions, made available to the market a novel transfection reagent FectoVIR®-AAV in May 2020. The reagent has been specifically developed to improve AAV (adeno-associated virus) production in suspension cell culture system for large-scale manufacturing.
AAVs are predominantly used in gene therapy development. To date there has been a significant and well-identified bottleneck in manufacturing sufficient amounts of AAV viral vectors to treat patients. This will continue to increase as more therapies are commercialized, and reach late stage clinical trials. Viral manufacturers, in order to increase capabilities, are looking for solutions to adapt key steps of production for large-scale manufacturing. Transient transfection is a critical step that is indispensable for a reliable industrial manufacturing process. Polyplus-transfection® has developed the FectoVIR®AAV transfection reagent to achieve large-scale transient transfection resulting in up to 10-fold increase in AAV functional viral titer yields in suspension cell systems.
Polyplus-transfection® developed the FectoVIR®-AAV transfection reagent in partnership with a range of viral manufacturers internationally. Rather than follow the industry standard model of developing a reagent for small-scale manufacturing and adapting for large-scale production, Polyplustransfection® has developed the entirely new reagent with large-scale transient transfection in mind, and then validated its use all the way through the R&D process.
The FectoVIR®-AAV transfection reagent fits within Polyplus-transfection®’s transfection reagent portfolio, which is the largest in the industry for the cell and gene therapy sector. This includes the PEIpro range, with PEIpro®-GMP, the first transfection solution for the gene and cell therapy industry that is compliant with global cGMP viral vector manufacturing requirements.
Polyplus-transfection® held a range of webinars to provide more details of the FectoVIR®-AAV product. Details can be found here: https://polyplus-transfection.webinargeek.com/fectovir-aav-a-giant-step-for-aav-large-scalemanufacturing?cst=website

Details of FectoVIR®-AAV can be accessed here: https://www.polyplus-transfection.com/products/fectovir-aav/

News

Tebubio : A complete range of solutions to optimize all your Biomanufacturing projects.

October 09, 2023

Since 1953, Tebubio facilitates Life Sciences research in France and throughout Europe. With over 80 team members across Europe, we provide researchers with a range of innovative solutions in many...

Learn more

Tebubio Laboratory : Access a personalized mini-scale mRNA production service

October 09, 2023

In response to the growing need for mRNA, Tebubio’s laboratories offer a mini-scale mRNA production service to quickly provide you with customised and optimised research grade sequences to be used...

Learn more

Microsynth France Le laboratoire de séquençage Sanger à Lyon

July 04, 2023

Learn more

Proteintechs GMP growth factors manufacturing facility, Chicago

July 04, 2023

Proteintech is a leading manufacturer of antibodies, immunoassays, proteins and Nanobodies. Overview of the Proteintech product range:  Antibodies against 13,000+ human targets. Trial size versions available.  Immunoassay kits...

Learn more

Myltenyi Biotech – New modules to expand processing capabilities of the CliniMACS Prodigy® Platform: electroporation and final formulation.

June 20, 2023

Learn more

Miltenyi Biotech – New automated process to simplify the manufacturing of gene-engineered NK Cells and Clinical-grade tumor-reactive T cell

June 20, 2023

The CliniMACS Prodigy® Tumor Reactive T (TRT) Cell Process offers a new, adaptable platform for scientists and clinicians working on tumor-infiltrating leukocyte (TIL) therapy, and can be tailored to the...

Learn more

Lumicks – Cell avidity: a new predictor of immune cell function and therapeutic success

June 20, 2023

Affinity between chimeric antigen receptor (CAR) T cells and their target have shown to be a poor predictor for T-cell function. On the contrary, cell avidity (or overall cellular binding...

Learn more

Miltenyi : New modules to expand processing capabilities of the CliniMACS Prodigy® Platform: electroporation and final formulation

August 05, 2022

The CliniMACS Prodigy represents the next generation in automated cell processing. This device offers advanced integrated solutions to streamline cell processing workflows – from cell separation through cell culture to...

Learn more

Gilson is pleased to partner with Syngoi Technologies to equip their latest GMP facility

August 04, 2022

We are pleased to announce that Gilson Connect solutions have been selected by Syngoi Technologies to enforce the traceability and repeatability of manual protocols. Syngoi Technologies is a biotechnology company...

Learn more

Gilson is pleased to partner with France Blood Transfusion Agency (EFS) Platform for Innovation in Biotherapies

August 03, 2022

Gilson is pleased to announce a new chapter of collaborating with the EFS Gene and Cell engineering unit of Bourgogne Franche Comté. The collaboration provides the EFS Development & Transfer...

Learn more

New automated process to simplify the manufacturing of gene-engineered NK Cells and Treg cells isolation

July 28, 2022

To address the variety of Treg cell applications, Miltenyi Biotec provides a broad range of tools for clinical use.

Learn more

CREAPHARM DEMONSTRATES UNPARALLELED PERFORMANCE OF -80°C NITROGEN TANK TECHNOLOGY

July 28, 2022

CREAPHARM BIOSERVICES has recently invested in -80°C nitrogen tanks to provide Biotechs and Research key players with a new solution to meet the challenges of ultra-low temperature storage.

Learn more

Videodrop, an ideal tool for the monitoring of bioproduction of Viral vectors

July 19, 2022

Today, Gene and Cell therapies are booming. However, due to the lack of solutions allowing rapid & continuous monitoring throughout the bioproduction process, Biotech’ companies are working “almost blind”. They...

Learn more

Measuring Size & concentration of nanoparticles

July 19, 2022

The Videodrop makes it possible to measure the size and concentration of biological nanoparticles like lentivirus, adenovirus or retrovirus

Learn more

Cytiva and Bayer to collaborate on allogeneic cell therapy manufacturing platform

July 12, 2022

Learn more

Article on improving viral vector production in GEN

July 12, 2022

GEN recently interviewed our Business Development Director, Dr. Natalia Elizalde, with whom they spoke about improving the production of lentiviral vectors, vectors that VIVEbiotech develops and manufactures.

Learn more

Cytiva and Nucleus Biologics join forces to accelerate development of custom cell media for cell and gene therapies

July 07, 2022

Cytiva, a global life sciences leader, and Nucleus Biologics, LLC, The Cell Performance Company™, have signed a collaboration agreement on custom media formulation and fulfillment solutions for the cell and...

Learn more

PharmaBoardoom points out VIVEbiotech as one of the ten Spanish Biotechs to watch in 2022

July 05, 2022

PharmaBoardroom, a leading British media specialized in the health sector, has published an article in which it highlights VIVEbiotech as one of the ten Spanish biotechs to follow in 2022.

Learn more

The Analytical Scientist interviews Rakel Lopez de Maturana

June 28, 2022

The Analytical Scientist interviewed Rakel Lopez de Maturana, VIVEbiotech´s Qualified Person & Regulatory Affairs Director.

Learn more

Gurutz Linazaroso, the CEO of VIVEbiotech, in the Medicine Maker Power List 2022

June 21, 2022

The CEO of VIVEbiotech, Dr. Gurutz Linazasoro, is part of the prestigious The Medicine Maker Power List.

Learn more

Interview with Natalia Elizalde in The Medicine Maker

June 14, 2022

The Business Development Director of VIVEbiotech Dr. Natalia Elizalde was interviewed by The Medicine Maker on the challenges of lentiviral vector manufacture/use.

Learn more

Plasmid DNA manufacturing – Soon a GMP Grade unit in TEMIS Santé, Besançon – Fr

April 19, 2022

Learn more

Landau Partnership

September 22, 2021

VectorBuilder Inc., a global leader in vector design, optimization and GMP manufacturing, and Landau Biotechnology Co., a world leader in developing nonhuman primate (NHP) models for clinical research applications, have...

Learn more

Univercells Partnership

September 16, 2021

VectorBuilder – a global leader in vector design, optimization, and GMP manufacturing – has formed a worldwide strategic partnership with Univercells Technologies, a provider of novel biomanufacturing technologies for flexible...

Learn more

The MACSima™ Imaging Platform is the only complete solution for ultra high content imaging experiments.

September 13, 2021

Learn more

New automated process to simplify the manufacturing of gene-engineered hematopoietic stem cells with the CliniMACS Prodigy® HSC Engineering System

September 13, 2021

Learn more

MedXCell SA

August 25, 2021

MedXCell Science SA: MedXCell Science SA was co-founded in 2018 by the University Hospital of Montpellier (CHU of Montpellier) in France and the Swiss company MedXCell SA. It was the...

Learn more

Cryoport Systems now supporting 7 commercial therapies globally

July 27, 2021

Learn more

Polyplus-transfection initiates construction of Vectura, a new 4,000m2 facility

July 23, 2021

Learn more

RD-Biotech: a new company from Besançon wins the « France Relance » call for projects

February 22, 2021

Following the unprecedented health crisis and its unprecedented economic impact, the Government has put in place numerous tools to support businesses.

Learn more

Covi-TRaC: arming our immune cells against SARS-COV2

September 11, 2020

A prolific period for researchers, confinement has allowed the Etablissement Français du Sang teams to generate and mature many ideas from pre-existing research. In Besançon, Marina Deschamps and Christophe Ferrand...

Learn more